LIFESTANCE HEALTH GROUP, INC. Financials LifeStance Health Group, Inc.
Equities
LFST
US53228F1012
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.2 USD | +0.65% |
|
+8.58% | -20.82% |
| Mar. 12 | LifeStance Health Appoints Teresa DeLuca to Its Board of Directors | CI |
| Mar. 06 | Jefferies Adjusts Price Target on LifeStance Health to $9 From $8, Maintains Buy Rating | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,562 | 1,857 | 2,964 | 2,370 | - | - |
| Enterprise Value (EV) 1 | 3,585 | 1,974 | 3,166 | 2,556 | 2,487 | 2,379 |
| P/E ratio | -9.07 x | -8.1 x | -15.4 x | -21.8 x | -28.6 x | -46.3 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 5.34 x | 2.16 x | 2.81 x | 1.94 x | 1.71 x | 1.51 x |
| EV / Revenue | 5.37 x | 2.3 x | 3 x | 2.1 x | 1.8 x | 1.52 x |
| EV / EBITDA | 72.9 x | 37.5 x | 53.6 x | 30.3 x | 20.6 x | 15.4 x |
| EV / FCF | -42.1 x | -74.6 x | -55.2 x | 242 x | 63.8 x | 41.7 x |
| FCF Yield | -2.37% | -1.34% | -1.81% | 0.41% | 1.57% | 2.4% |
| Price to Book | 2.31 x | 1.22 x | 2.08 x | 1.7 x | 1.72 x | 1.72 x |
| Nbr of stocks (in thousands) | 374,149 | 375,986 | 378,607 | 382,239 | - | - |
| Reference price 2 | 9.520 | 4.940 | 7.830 | 6.200 | 6.200 | 6.200 |
| Announcement Date | 3/10/22 | 3/8/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 377.2 | 667.5 | 859.5 | 1,056 | 1,219 | 1,382 | 1,566 |
| EBITDA 1 | - | 49.15 | 52.67 | 59.04 | 84.4 | 120.8 | 154.8 |
| EBIT 1 | - | -286.4 | -210.2 | -189.1 | -93.87 | -66.62 | -36.68 |
| Operating Margin | - | -42.9% | -24.45% | -17.92% | -7.7% | -4.82% | -2.34% |
| Earnings before Tax (EBT) 1 | - | -333.1 | -232.7 | -206.6 | -111.6 | -85.34 | -60.83 |
| Net income 1 | -311.3 | -343.9 | -215.6 | -186.3 | -103.6 | -76.08 | -47.85 |
| Net margin | -82.53% | -51.53% | -25.08% | -17.64% | -8.5% | -5.5% | -3.06% |
| EPS 2 | - | -1.050 | -0.6100 | -0.5100 | -0.2845 | -0.2165 | -0.1338 |
| Free Cash Flow 1 | - | -85.07 | -26.47 | -57.4 | 10.57 | 39 | 57 |
| FCF margin | - | -12.74% | -3.08% | -5.44% | 0.87% | 2.82% | 3.64% |
| FCF Conversion (EBITDA) | - | - | - | - | 12.53% | 32.27% | 36.83% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 4/12/21 | 3/10/22 | 3/8/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 173.8 | 190.1 | 203.1 | 209.5 | 217.6 | 229.4 | 252.6 | 259.6 | 262.9 | 280.6 | 299 | 305.7 | 303.5 | 315 | 333 |
| EBITDA 1 | 10.69 | 11.4 | 12.48 | 14.63 | 15.38 | 10.18 | 10.1 | 14.06 | 14.58 | 20.29 | 20.64 | 20.36 | 20.66 | 23.95 | 27.16 |
| EBIT 1 | -124.7 | -113.8 | -64.85 | -60.47 | -38.84 | -46.01 | -34.09 | -48.41 | -74.36 | -32.27 | -25.4 | -27.4 | -26.4 | -23.9 | - |
| Operating Margin | -71.72% | -59.84% | -31.93% | -28.86% | -17.85% | -20.06% | -13.5% | -18.65% | -28.28% | -11.5% | -8.5% | -8.96% | -8.7% | -7.59% | - |
| Earnings before Tax (EBT) 1 | -129.2 | -118.6 | -69 | -67.8 | -42.21 | -53.72 | -38.28 | -52.02 | -77.97 | -38.32 | -33 | -30 | -30 | -28 | - |
| Net income 1 | -120.5 | -144.8 | -62.33 | -68.73 | -37.85 | -46.66 | -34.24 | -45.48 | -61.58 | -44.96 | -30.75 | -29.15 | -28.2 | -25.85 | - |
| Net margin | -69.29% | -76.16% | -30.69% | -32.8% | -17.4% | -20.34% | -13.56% | -17.52% | -23.42% | -16.02% | -10.29% | -9.54% | -9.29% | -8.21% | - |
| EPS 2 | -0.3500 | -0.3200 | -0.1800 | -0.1900 | -0.1100 | -0.1300 | -0.0900 | -0.1300 | -0.1700 | -0.1200 | -0.0879 | -0.0714 | -0.0700 | -0.0672 | -0.0585 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 3/10/22 | 5/9/22 | 8/9/22 | 11/8/22 | 3/8/23 | 5/10/23 | 8/9/23 | 11/8/23 | 2/28/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 23.5 | 116 | 201 | 186 | 117 | 8.96 |
| Net Cash position 1 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 0.4783 x | 2.211 x | 3.412 x | 2.201 x | 0.9708 x | 0.0579 x |
| Free Cash Flow 1 | - | -85.1 | -26.5 | -57.4 | 10.6 | 39 | 57 |
| ROE (net income / shareholders' equity) | - | -27.1% | -14.1% | -12.6% | -7.3% | -5.03% | -3.32% |
| ROA (Net income/ Total Assets) | - | -19.7% | -10.5% | -8.7% | -5.07% | -3.9% | -3.18% |
| Assets 1 | - | 1,748 | 2,050 | 2,142 | 2,043 | 1,953 | 1,505 |
| Book Value Per Share 2 | - | 4.130 | 4.040 | 3.770 | 3.650 | 3.610 | 3.600 |
| Cash Flow per Share 2 | - | 0.0300 | 0.1500 | -0.0500 | 0.1100 | 0.2400 | - |
| Capex 1 | - | 94.5 | 79.3 | 40.5 | 39.4 | 57.7 | 69.3 |
| Capex / Sales | - | 14.16% | 9.22% | 3.84% | 3.23% | 4.17% | 4.43% |
| Announcement Date | 4/12/21 | 3/10/22 | 3/8/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
6.2
USD
Average target price
8.786
USD
Spread / Average Target
+41.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.82% | 2.37B | |
| -14.92% | 84.68B | |
| +13.30% | 81.12B | |
| +11.62% | 29.59B | |
| -12.71% | 16.73B | |
| -2.42% | 16.36B | |
| -2.63% | 14.92B | |
| -31.58% | 11.77B | |
| -0.47% | 11.72B | |
| +27.44% | 11.71B |
- Stock Market
- Equities
- LFST Stock
- Financials LifeStance Health Group, Inc.
